SCHEDULE 13G/A: TCG Crossover Divests Entire Cidara Therapeutics Stake

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have filed an amended Schedule 13G, reporting zero beneficial ownership in Cidara Therapeutics, Inc. common stock.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu (the Reporting Persons) filed an Amendment No. 1 to their Schedule 13G.
• The amendment indicates that as of September 30, 2025, the Reporting Persons beneficially own 0.00 shares of Cidara Therapeutics, Inc. common stock.
• This represents 0% of the class of securities, signifying a complete divestment of their previous holdings.
• The filing updates their original Schedule 13G, which was filed on December 3, 2024.

Sentiment

Score: 3

Explanation: The complete divestment of shares by TCG Crossover, a significant institutional investor, signals a lack of confidence or a strategic shift away from Cidara Therapeutics, which is generally perceived negatively by the market.

Negatives

• The complete divestment of shares by TCG Crossover, a significant institutional investor, could be interpreted by the market as a lack of confidence in Cidara Therapeutics' future prospects.
• This action may lead to negative market sentiment and potential downward pressure on the company's stock price.

Risks

• Potential negative market perception and investor reaction due to a significant institutional investor divesting its entire stake in the company.
• Increased scrutiny from other investors regarding the underlying reasons for the divestment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Cidara Therapeutics, Inc. It solely reports a change in beneficial ownership by an external investor.

Industry Context

A complete divestment by a crossover fund like TCG Crossover, which typically invests in both private and public companies, can signal a strategic shift in their portfolio or specific concerns about the therapeutics sector or Cidara's pipeline. This action could influence other institutional investors' perceptions of the company and the broader biotech market, particularly for companies in similar development stages.

Stakeholder Impact

• Shareholders: May react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price and reduced investor confidence.
• Company Management: Could face increased scrutiny and questions from the market regarding the reasons for the divestment and its implications for future investor relations and funding.

Key Dates

Recommendation

The complete divestment by a sophisticated institutional investor like TCG Crossover suggests a loss of conviction in Cidara Therapeutics' future prospects. This action often precedes or reflects underlying negative developments, making a 'sell' recommendation prudent for investors to mitigate potential downside risk and re-evaluate their position.

Keywords

Cidara Therapeutics, TCG Crossover, Schedule 13G, beneficial ownership, common stock, institutional ownership, divestment, biotechnology